Imagion Biosystems gives notice that, on 20 October 2020 the Company issued 2,401,900 fully paid ordinary shares (Shares) in the Company as the result of shareholder exercising their options in the Company.
Read the notice.
Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent
January 31, 2026
Imagion Biosystems Hits Major Milestone, Submits IND Application to U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent Key Highlights: Imagion Biosystems has